Research programme: epigenetic cancer therapeutics - Beactica

Drug Profile

Research programme: epigenetic cancer therapeutics - Beactica

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beactica
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone demethylase inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 02 Jun 2017 Beactica enters into a collaboration with Uppsala University and SciLifeLab in Sweden for Beactica's LSD1 inhibitors in Cancer
  • 26 Oct 2016 Epigenetic cancer therapeutics licensed to Dong AST worldwide
  • 20 Nov 2014 Early research in Cancer in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top